Cargando…

Presentation of a T Cell Receptor Antagonist Peptide by Immunoglobulins Ablates Activation of  T Cells by a Synthetic Peptide or Proteins Requiring Endocytic Processing

T cell receptor (TCR) antagonism is being considered for inactivation of aggressive T cells and reversal of T cell–mediated autoimmune diseases. TCR antagonist peptides silence aggressive T cells and reverse experimental allergic encephalomyelitis induced with free peptides. However, it is not clear...

Descripción completa

Detalles Bibliográficos
Autores principales: Legge, Kevin L., Min, Booki, Potter, Nicholas T., Zaghouani, Habib
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 1997
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2196232/
https://www.ncbi.nlm.nih.gov/pubmed/9091578
_version_ 1782148018396463104
author Legge, Kevin L.
Min, Booki
Potter, Nicholas T.
Zaghouani, Habib
author_facet Legge, Kevin L.
Min, Booki
Potter, Nicholas T.
Zaghouani, Habib
author_sort Legge, Kevin L.
collection PubMed
description T cell receptor (TCR) antagonism is being considered for inactivation of aggressive T cells and reversal of T cell–mediated autoimmune diseases. TCR antagonist peptides silence aggressive T cells and reverse experimental allergic encephalomyelitis induced with free peptides. However, it is not clear whether free antagonist peptides could reverse natural disease where the antigen is presumably available for endocytic processing and peptides gain access to newly synthesized class II MHC molecules. Using an efficient endocytic presentation system, we demonstrate that a proteolipid protein (PLP) TCR antagonist peptide (PLP-LR) presented on an Ig molecule (IgPLP-LR) abrogates the activation of T cells stimulated with free encephalitogenic PLP peptide (PLP1), native PLP, or an Ig containing PLP1 peptide (Ig-PLP1). Free PLP-LR abolishes T cell activation when the stimulator is free PLP1 peptide, but has no measurable effect when the stimulator is the native PLP or Ig-PLP1. In vivo, Ig-PLP1 induces a T cell response to PLP1 peptide. However, when coadministered with Ig-PLP-LR, the response to PLP1 peptide is markedly reduced whereas the response to PLP-LR is normal. Free PLP-LR coadministered with Ig-PLP1 has no effect on the T cell response to PLP1. These findings indicate that endocytic presentation of an antagonist peptide by Ig outcompete both external and endocytic agonist peptides whereas free antagonist hinders external but not endocytic agonist peptide. Direct contact with antagonist ligand and/or trans-regulation by PLP-LR–specific T cells may be the operative mechanism for Ig-PLP-LR–mediated downregulation of PLP1-specific T cells in vivo. Efficient endocytic presentation of antagonist peptides, which is the fundamental event for either mechanism, may be critical for reversal of spontaneous T cell–mediated autoimmune diseases where incessant endocytic antigen processing could be responsible for T cell aggressivity.
format Text
id pubmed-2196232
institution National Center for Biotechnology Information
language English
publishDate 1997
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21962322008-04-16 Presentation of a T Cell Receptor Antagonist Peptide by Immunoglobulins Ablates Activation of  T Cells by a Synthetic Peptide or Proteins Requiring Endocytic Processing Legge, Kevin L. Min, Booki Potter, Nicholas T. Zaghouani, Habib J Exp Med Article T cell receptor (TCR) antagonism is being considered for inactivation of aggressive T cells and reversal of T cell–mediated autoimmune diseases. TCR antagonist peptides silence aggressive T cells and reverse experimental allergic encephalomyelitis induced with free peptides. However, it is not clear whether free antagonist peptides could reverse natural disease where the antigen is presumably available for endocytic processing and peptides gain access to newly synthesized class II MHC molecules. Using an efficient endocytic presentation system, we demonstrate that a proteolipid protein (PLP) TCR antagonist peptide (PLP-LR) presented on an Ig molecule (IgPLP-LR) abrogates the activation of T cells stimulated with free encephalitogenic PLP peptide (PLP1), native PLP, or an Ig containing PLP1 peptide (Ig-PLP1). Free PLP-LR abolishes T cell activation when the stimulator is free PLP1 peptide, but has no measurable effect when the stimulator is the native PLP or Ig-PLP1. In vivo, Ig-PLP1 induces a T cell response to PLP1 peptide. However, when coadministered with Ig-PLP-LR, the response to PLP1 peptide is markedly reduced whereas the response to PLP-LR is normal. Free PLP-LR coadministered with Ig-PLP1 has no effect on the T cell response to PLP1. These findings indicate that endocytic presentation of an antagonist peptide by Ig outcompete both external and endocytic agonist peptides whereas free antagonist hinders external but not endocytic agonist peptide. Direct contact with antagonist ligand and/or trans-regulation by PLP-LR–specific T cells may be the operative mechanism for Ig-PLP-LR–mediated downregulation of PLP1-specific T cells in vivo. Efficient endocytic presentation of antagonist peptides, which is the fundamental event for either mechanism, may be critical for reversal of spontaneous T cell–mediated autoimmune diseases where incessant endocytic antigen processing could be responsible for T cell aggressivity. The Rockefeller University Press 1997-03-17 /pmc/articles/PMC2196232/ /pubmed/9091578 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Article
Legge, Kevin L.
Min, Booki
Potter, Nicholas T.
Zaghouani, Habib
Presentation of a T Cell Receptor Antagonist Peptide by Immunoglobulins Ablates Activation of  T Cells by a Synthetic Peptide or Proteins Requiring Endocytic Processing
title Presentation of a T Cell Receptor Antagonist Peptide by Immunoglobulins Ablates Activation of  T Cells by a Synthetic Peptide or Proteins Requiring Endocytic Processing
title_full Presentation of a T Cell Receptor Antagonist Peptide by Immunoglobulins Ablates Activation of  T Cells by a Synthetic Peptide or Proteins Requiring Endocytic Processing
title_fullStr Presentation of a T Cell Receptor Antagonist Peptide by Immunoglobulins Ablates Activation of  T Cells by a Synthetic Peptide or Proteins Requiring Endocytic Processing
title_full_unstemmed Presentation of a T Cell Receptor Antagonist Peptide by Immunoglobulins Ablates Activation of  T Cells by a Synthetic Peptide or Proteins Requiring Endocytic Processing
title_short Presentation of a T Cell Receptor Antagonist Peptide by Immunoglobulins Ablates Activation of  T Cells by a Synthetic Peptide or Proteins Requiring Endocytic Processing
title_sort presentation of a t cell receptor antagonist peptide by immunoglobulins ablates activation of  t cells by a synthetic peptide or proteins requiring endocytic processing
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2196232/
https://www.ncbi.nlm.nih.gov/pubmed/9091578
work_keys_str_mv AT leggekevinl presentationofatcellreceptorantagonistpeptidebyimmunoglobulinsablatesactivationoftcellsbyasyntheticpeptideorproteinsrequiringendocyticprocessing
AT minbooki presentationofatcellreceptorantagonistpeptidebyimmunoglobulinsablatesactivationoftcellsbyasyntheticpeptideorproteinsrequiringendocyticprocessing
AT potternicholast presentationofatcellreceptorantagonistpeptidebyimmunoglobulinsablatesactivationoftcellsbyasyntheticpeptideorproteinsrequiringendocyticprocessing
AT zaghouanihabib presentationofatcellreceptorantagonistpeptidebyimmunoglobulinsablatesactivationoftcellsbyasyntheticpeptideorproteinsrequiringendocyticprocessing